Concepedia

Mohini Rajasagi

MR

Statistics

Publications

5

Citations

1.1K

H-Index

5

Active since

2012

Affiliations

Harvard University(Current)

Dana-Farber Cancer Institute

The University of Texas MD Anderson Cancer Center

Massachusetts General Hospital

Brigham and Women's Hospital

Mohini Rajasagi is an author at Harvard University specializing in oncology, monoclonal antibodies, and pembrolizumab therapy.

Publications per year

2012–2020

5

Publications

5

Comprehensive analysis of cancer-associated somatic mutations in class I HLA genes

Sachet A. Shukla, Michael S. Rooney, Mohini Rajasagi et al. · Nature Biotechnology · 2015 · 694 citations · Full text

, , +14

Systematic identification of personal tumor-specific neoantigens in chronic lymphocytic leukemia

Mohini Rajasagi, Sachet A. Shukla, Edward F. Fritsch et al. · Blood · 2014 · 308 citations · Full text

, , +16

CD40L-Tri, a novel formulation of recombinant human CD40L that effectively activates B cells

Masayasu Naito, Ursula Hainz, Ute Burkhardt et al. · Cancer Immunology Immunotherapy · 2012 · 38 citations · Full text

, , +17

1400P Vibostolimab, an anti-TIGIT antibody, as monotherapy and in combination with pembrolizumab in anti-PD-1/PD-L1-refractory NSCLC

M-J. Ahn, Jiaxin Niu, Dongwook Kim et al. · Annals of Oncology · 2020 · 29 citations

, , +14

1410P Safety and efficacy of vibostolimab, an anti-TIGIT antibody, plus pembrolizumab in patients with anti-PD-1/PD-L1-naive NSCLC

Jiaxin Niu, Adnan Nagrial, Mark Voskoboynik et al. · Annals of Oncology · 2020 · 22 citations

, , +14

1–5 of 5